Here's Why Altimmune Stock Is Surging Today
Shares of Altimmune (NASDAQ: ALT), a clinical-stage biopharmaceutical company, are on the move following a positive clinical readout. Investors excited about the company's potential new weight loss drug drove the stock 23% higher as of 12:34 p.m. on Wednesday.
Altimmune's weight loss drug candidate, ALT-801, is a GLP-1 receptor agonist that also activates glucagon receptors. There are other GLP-1 drugs out there that promote weight loss by regulating appetites. Boosting energy expenditure by acting on glucagon receptors, though, could give ALT-801 a unique advantage over Saxenda and Wegovy from Novo Nordisk (NYSE: NVO).
Image source: Getty Images.
Source Fool.com
